Po-Chien Shen1, Wei-Chou Chang2, Cheng-Hsiang Lo1, Jen-Fu Yang1, Meei-Shyuan Lee3, Yang-Hong Dai1, Chun-Shu Lin1, Chao-Yueh Fan1, Wen-Yen Huang4. 1. Department of Radiation Oncology, Tri-Service General Hospital, National Defense Medical Center, Taiwan. 2. Department of Radiology, Tri-Service General Hospital, National Defense Medical Center, Taiwan. 3. School of Public Health, National Defense Medical Center, Taipei, Taiwan. 4. Department of Radiation Oncology, Tri-Service General Hospital, National Defense Medical Center, Taiwan; Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan. Electronic address: hwyyi@yahoo.com.tw.
Abstract
PURPOSE: This study compared the local control and overall survival (OS) between stereotactic body radiation therapy (SBRT) and transarterial chemoembolization (TACE) in medium-sized (3-8 cm) hepatocellular carcinoma (HCC). METHODS AND MATERIALS: From January 2008 to October 2017, 188 patients with medium-sized HCC underwent either TACE (n = 142) or SBRT (n = 46). We adjusted for imbalances in treatment assignment using propensity score matching. Infield control (IFC) and OS were analyzed retrospectively. RESULTS: The median follow-up time was 17.1 months for all patients and 26.6 months for surviving patients. The 3-year IFC was 63.0% for the TACE group and 73.3% for the SBRT group. Multivariable analysis identified the independent predictors for IFC as treatment modality (SBRT vs TACE), sex (female vs male), and recurrence status (recurrence vs new diagnosis). The 3-year OS was 22.9% for the TACE group and 47.4% for the SBRT group. Multivariable analysis identified the independent predictors of OS as number of tumors, treatment modality (SBRT vs TACE), albumin-bilirubin grade, tumor volume, Eastern Cooperative Oncology Group status, and recurrence status. Propensity score matching analysis revealed that the SBRT group had better IFC (3-year IFC of 77.5% vs 55.6%; P = .007) and OS (3-year OS of 55.0% vs 13.0%; P < .001) than the TACE group. For recurrent HCC, the SBRT group exhibited superior IFC (3-year IFC of 75% vs 57.5%; P = .022) and OS (3-year OS of 58.3% vs 5.9%; P < .001) compared with the TACE group. However, there was no difference in IFC or OS between TACE and SBRT for patients with newly diagnosed HCC. CONCLUSIONS: SBRT has better IFC and OS rates than TACE in patients with medium-sized HCC, particularly for recurrent cases, which warrants prospective randomized controlled trials of TACE and SBRT.
PURPOSE: This study compared the local control and overall survival (OS) between stereotactic body radiation therapy (SBRT) and transarterial chemoembolization (TACE) in medium-sized (3-8 cm) hepatocellular carcinoma (HCC). METHODS AND MATERIALS: From January 2008 to October 2017, 188 patients with medium-sized HCC underwent either TACE (n = 142) or SBRT (n = 46). We adjusted for imbalances in treatment assignment using propensity score matching. Infield control (IFC) and OS were analyzed retrospectively. RESULTS: The median follow-up time was 17.1 months for all patients and 26.6 months for surviving patients. The 3-year IFC was 63.0% for the TACE group and 73.3% for the SBRT group. Multivariable analysis identified the independent predictors for IFC as treatment modality (SBRT vs TACE), sex (female vs male), and recurrence status (recurrence vs new diagnosis). The 3-year OS was 22.9% for the TACE group and 47.4% for the SBRT group. Multivariable analysis identified the independent predictors of OS as number of tumors, treatment modality (SBRT vs TACE), albumin-bilirubin grade, tumor volume, Eastern Cooperative Oncology Group status, and recurrence status. Propensity score matching analysis revealed that the SBRT group had better IFC (3-year IFC of 77.5% vs 55.6%; P = .007) and OS (3-year OS of 55.0% vs 13.0%; P < .001) than the TACE group. For recurrent HCC, the SBRT group exhibited superior IFC (3-year IFC of 75% vs 57.5%; P = .022) and OS (3-year OS of 58.3% vs 5.9%; P < .001) compared with the TACE group. However, there was no difference in IFC or OS between TACE and SBRT for patients with newly diagnosed HCC. CONCLUSIONS: SBRT has better IFC and OS rates than TACE in patients with medium-sized HCC, particularly for recurrent cases, which warrants prospective randomized controlled trials of TACE and SBRT.
Authors: Josep M Llovet; Robin Kate Kelley; Augusto Villanueva; Amit G Singal; Eli Pikarsky; Sasan Roayaie; Riccardo Lencioni; Kazuhiko Koike; Jessica Zucman-Rossi; Richard S Finn Journal: Nat Rev Dis Primers Date: 2021-01-21 Impact factor: 52.329
Authors: Siu Hin Mak; Sean Man Natalie Wong; Wan Hang Keith Chiu; Chi Leung Chiang; Wing Ling Winnie Yip; Hoi Man Connie Ho; Sin Yu Cynthia Yeung; Ka Heng Mark Chan; Wan Yan Venus Lee; Ann Shing Francis Lee Journal: Strahlenther Onkol Date: 2022-01-06 Impact factor: 4.033
Authors: Josep M Llovet; Thierry De Baere; Laura Kulik; Philipp K Haber; Tim F Greten; Tim Meyer; Riccardo Lencioni Journal: Nat Rev Gastroenterol Hepatol Date: 2021-01-28 Impact factor: 46.802
Authors: Thomas B Brunner; Dominik Bettinger; Michael Schultheiss; Lars Maruschke; Lukas Sturm; Nico Bartl; Ivana Koundurdjieva; Simon Kirste; Hannes P Neeff; Christian Goetz; Nils Henrik Nicolay; Gabriele Ihorst; Fabian Bamberg; Robert Thimme; Anca-Ligia Grosu; Eleni Gkika Journal: Front Oncol Date: 2021-03-19 Impact factor: 6.244